Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A
Go back to Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A| Beam Inc. (NASDAQ: BEAM) | Delayed: 34.14 +1.66 (5.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.48 | 52 Week High | $83.60 | |||
| Open | $33.58 | 52 Week Low | $82.96 | |||
| Day High | $34.35 | P/E | 15.24 | |||
| Day Low | $32.66 | EPS | $2.24 | |||
| Volume | 3,509,476 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 34.14 +1.66 (5.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.48 | 52 Week High | $83.60 | |||
| Open | $33.58 | 52 Week Low | $82.96 | |||
| Day High | $34.35 | P/E | 15.24 | |||
| Day Low | $32.66 | EPS | $2.24 | |||
| Volume | 3,509,476 | |||||
